- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$0.99 BnMarket Estimate, 2026
$1.15 BnMarket Forecast, 2034
$3.81 BnCAGR, 2026–2034
16.2%Executive Summary: North America Non-Invasive Prenatal Testing Market
- Market Scope: Comprehensive regional analysis of North America's non-invasive prenatal testing (NIPT) sector, detailing testing instruments, methodology frameworks, clinical applications, end-user settings, regulatory factors, and country-level profiles (forecast period: 2026-2034).
- Market Valuation: Valued at USD 0.99 billion in 2025, reaching USD 1.15 billion in 2026, and projected to expand to USD 3.81 billion by 2034, growing at a robust CAGR of 16.20% from 2026 to 2034.
- Primary Growth Drivers: Rising preference for non-invasive techniques over invasive procedures (e.g., amniocentesis), growing maternal age leading to higher chromosomal abnormality risks, improving insurance reimbursement policies, and continuous technological advancements in NGS and bioinformatics.
Key Market Segment Metrics
| Category | Leading Segment (Base Position) | Fastest-Growing / High-Growth Segment (2026-2034) |
|---|---|---|
| By Instruments | NGS (Next-Generation Sequencing - dominated share, driven by high-throughput precision in genomic analysis and cell-free DNA sequencing) | PCR & Microarray Systems (projected at high growth rates, fueled by rapid turnaround times and cost-effective targeted screening panels) |
| By Method | Cf-DNA (Cell-free DNA - captured major market share due to high sensitivity, early detection windows, and superior diagnostic accuracy) | FCMB (Fetal Cells-based Methods - expected to register accelerated growth through advanced isolation techniques for rare fetal cell capture) |
| By Application | Trisomy (held the dominant share, supported by widespread clinical screening guidelines for Down syndrome and other chromosomal trisomies) | Microdeletion & Genetics (projected at an extraordinary CAGR, propelled by expanded panel testing for rare monogenic diseases and genetic disorders) |
| By End User | Diagnostic Labs (market leader holding the major share, backed by centralized high-volume testing capabilities and specialized clinical infrastructure) | Hospitals (experiencing rapid adoption growth driven by point-of-care obstetric care integrations and expanding maternal-fetal medicine departments) |
| By Country | The United States (market leader with a major regional share, backed by advanced healthcare infrastructure and expanding insurance coverage) | Canada (key growth hub driven by increasing healthcare investments, rising adoption of advanced prenatal screenings, and favorable clinical guidelines) |
Major Market Players & Industry Landscape
Market Structure: Highly consolidated, innovation-driven environment characterized by strategic partnerships, portfolio expansions, and inorganic collaborations among major genomic analytics companies and healthcare institutions to enhance commercialization capabilities throughout the 2026-2034 horizon.
Key Companies: GE Healthcare, Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN N.V., Agilent Technologies, Inc., and Beijing Genomics Institute.
Download Free Sample Report
North America Non-Invasive Prenatal Testing Market Size
The North America Non-Invasive Prenatal Testing Market is projected to grow from USD 0.99 billion in 2025 to USD 1.15 billion in 2026 and reach USD 3.81 billion by 2034, registering a CAGR of 16.20% during the forecast period from 2026 to 2034.
The market for the non-invasive prenatal testing market is most likely to be driven by a rising preference for non-invasive techniques over invasive methods and growing awareness of non-invasive prenatal testing. Also, the high risk of chromosomal abnormalities with growing maternal age is expected to drive the market. Moreover, improving reimbursement scenarios for Non-Invasive Prenatal Testing and growing product usage in new applications is influencing the market growth in the region. Additionally, advancements in current tests in enhanced functionalities, better chemistry, and bioinformatics analysis are expected to drive market growth.
The benefits of these tests over more comprehensive and invasive procedures like amniocentesis and chronic villus collection have boosted NIPT testing usage. These benefits are more likely to promote the acceptance of such treatments, resulting in the market's rapid growth.
Furthermore, technological advancements in the detection of monogenic diseases enhance market revenue. Progenity, Inc., for example, introduced Resura in April 2019 to enhance its portfolio in contrast to other competitive tests on the market. Resura is a prenatal test for a monogenic illness that utilizes sequencing-based non-invasive cell-free DNA technology.
The American College of Obstetricians and Gynecologists (ACOG) collaborated with the Society for Maternal-Fetal Medicine (SMFM) to release recommendations on aneuploidy screening options, which prompted this coverage (SMFM). One of the market's main driving forces is improving payment policies for ordinary and low-risk pregnancies. For example, Natera announced in December 2020 that their non-invasive prenatal testing (NIPT) would be covered by the most extensive U.S. health plan, Aetna, for all pregnancies.
Owing to the rise in genetic diseases, increased awareness of early fetal testing, and growing maternal age, the market demand for non-invasive prenatal testing is projected to rise over the forecast period. In addition, the developed countries such as the United States and Canada have witnessed advanced healthcare infrastructure, technological advancement in the healthcare sector, which are expected to provide lucrative growth opportunities for the new market entrants.
However, a dearth of skilled professionals is restraining the growth of this market. Also, a lack of test accessibility, ethical issues, and strict government restrictions are only a few reasons that will limit the North American NIPT market's growth.
MARKET SEGMENTATION
This research report on the North American Non-Invasive Prenatal Testing Market has been segmented and sub-segmented into the following categories.
By Instruments
-
Ultrasound
-
NGS
- PCR
- Microarray
By Method
-
FCMB
-
Cf-DNA
By Application
-
Trisomy
-
Microdeletion
- Genetics
- Rh Factor
By End User
-
Hospitals
-
Diagnostic Labs
By Country
-
The United States
-
Canada
- Rest of North America
Regionally, North America took the major chunk of the Global Non-Invasive Prenatal Testing Market share in 2023, with the U.S. accounting for a major share.
Globally, North America dominated the Non-Invasive Prenatal Testing Market and accounted for the revenue share of over 45.9 % in 2023. The market growth in the region is attributed to the technological advancements in the healthcare sector, favourable reimbursement policies, and rising preference for non-invasive techniques over invasive methods. Although the United States lacks national consensus policies on NIPT implementation, it is extensively embraced across the country, resulting in North America's dominance. As a result, in the North American regional market, the United States dominated the market growth and held the highest share over the forecast period. The country's major companies concentrate on inorganic strategies with the industry's leading players to enhance their research and commercialization capabilities, which are projected to generate substantial market revenue.
Furthermore, major insurance companies' recent inclusion of NIPT in their coverage plans is expected to promote market growth in the United States. In addition, Illumina won a patent infringement case against Roche's Ariosa Diagnostics (Roche) in June 2019. on the other hand, the Canadian Non-Invasive Prenatal Testing Market is anticipated to account for a moderate share and contribute to the regional market growth.
KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE
A few of the prominent companies operating in the North America Non-Invasive Prenatal Testing Market profiled in the report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).